CervoMed (CRVO) Change in Receivables (2011 - 2026)
CervoMed (CRVO) posted Change in Receivables of -$426993.0 for Q1 2026, up 54.3% sequentially from -$934394.0 in Q4 2025, and up 31.68% YoY from -$324261.8 in Q1 2025.
CervoMed (CRVO) Change in Receivables (2011 - 2026) Analysis & Trends
CervoMed has reported Change in Receivables for 5 years, with the latest figure at -$426993.0 in Q1 2026.
- Quarterly Change in Receivables rose 31.68% year-over-year to -$426993.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 200.0% YoY) and the FY2025 annual result came in at -$1.8 million, down 236.48% from the prior year.
- Change in Receivables advanced to -$426993.0 in Q1 2026 per CRVO's latest filing, from -$934394.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $2.0 million in Q4 2024 and troughed at -$999588.0 in Q3 2025.
- A 4-year average of $0.0 and a median of -$426993.0 in 2026 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables jumped 117.4% in 2024, then tumbled 478.42% in 2025.
- Over 4 years, Change in Receivables stood at $915404.0 in 2023, then surged by 117.4% to $2.0 million in 2024, then tumbled by 146.95% to -$934394.0 in 2025, then soared by 54.3% to -$426993.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$426993.0, -$934394.0, and -$999588.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -426,993.00 |
| Mar 31, 2026 | -426,993.00 |
| Dec 31, 2025 | -934,394.00 |
| Dec 31, 2025 | -934,394.00 |
| Sep 30, 2025 | -999,588.00 |
| Sep 30, 2025 | -999,588.00 |
| Jun 30, 2025 | 731,748.00 |
| Jun 30, 2025 | 731,748.00 |
| Mar 31, 2025 | -625,004.00 |
| Mar 31, 2025 | -625,004.00 |
| Dec 31, 2024 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 264,148.00 |
| Sep 30, 2024 | 264,148.00 |
| Mar 31, 2024 | -915,404.00 |
| Mar 31, 2024 | -915,404.00 |
| Dec 31, 2023 | 915,404.00 |
| Dec 31, 2023 | 915,404.00 |
| Sep 30, 2011 | -5,000.00 |
| Sep 30, 2011 | -5,000.00 |